<DOC>
	<DOCNO>NCT01834079</DOCNO>
	<brief_summary>This Single arm , Single centre trial check safety efficacy bone marrow derive autologous mono nuclear cell ( 100 million per dose ) clinical trial conduct 36 month patient optic nerve disease .</brief_summary>
	<brief_title>Study Safety Efficacy Bone Marrow Derived Autologous Cells Treatment Optic Nerve Disease</brief_title>
	<detailed_description>Optic Nerve Diseases : Conditions produce injury dysfunction second cranial optic nerve , generally consider component central nervous system . Damage optic nerve fibre may occur near origin retina , optic disk , nerve , optic chiasm , optic tract , lateral geniculate nucleus . Clinical manifestation may include decreased visual acuity contrast sensitivity , impaired color vision , afferent papillary defect . primary put clinical study measure Improvement visual loss improvement idiopathic intra cranial.This Single arm , Single centre trial check safety efficacy bone marrow derive autologous mono nuclear cell ( 100 million per dose ) clinical trial conduct 36 month .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Optic Atrophy</mesh_term>
	<mesh_term>Optic Nerve Diseases</mesh_term>
	<criteria>Patient Should suffer Optic Nerve diseases Like Diabetic Retinopathy , retinal pigmentation age 18 50 Willingness undergo Bone Marrow derive autologous cell therapy . Ability comprehend explain protocol thereafter give informed consent well sign require Informed consent form ( ICF ) study . A ability willingness regular visit hospital protocol follow . Patients pre exist Current systemic disease lung , liver ( exception ; History uncomplicated Hepatitis A ) , gastrointestinal , Cardiac , Immunodeficiency , ( include HIV ) Or laboratory Investigation could cause neurological defect include Syphilis , clinically relevant polyneuropathy ) etc . History Life threaten Allergic immune mediate reaction Haemodynamically Unstable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Optic Atrophy , Stem cell therapy</keyword>
</DOC>